Corbus Pharmaceuticals Holdings (CRBP) Net Equity Issued and Repurchased (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Net Equity Issued and Repurchased of $2.9 million for Q3 2025, down 91.99% year-over-year from $35.6 million in Q3 2024, and up 22030.77% quarter-over-quarter from -$13000.0 in Q4 2024.
Corbus Pharmaceuticals Holdings (CRBP) Net Equity Issued and Repurchased (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at $2.9 million for Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased fell 91.99% year-over-year to $2.9 million; the TTM figure through Sep 2025 stood at $2.8 million (down 98.44% YoY), while the FY2024 annual figure was $182.1 million, up 343405.66% from the prior year.
- Net Equity Issued and Repurchased for Q3 2025 stood at $2.9 million, up from -$13000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $108.9 million in Q1 2024, with the low at -$74000.0 in Q4 2023.
- The 4-year median for Net Equity Issued and Repurchased is $1.5 million (2023), against an average of $24.7 million.
- The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased jumped 508471.43% in 2024, then tumbled 91.99% in 2025.
- Corbus Pharmaceuticals Holdings' Net Equity Issued and Repurchased stood at $62.5 million in 2021, then plunged by 100.12% to -$74000.0 in 2023, then jumped by 82.43% to -$13000.0 in 2024, then jumped by 22030.77% to $2.9 million in 2025.
- Business Quant data shows CRBP's Net Equity Issued and Repurchased at $2.9 million in Q3 2025, -$13000.0 in Q4 2024, and $35.6 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.85 Mn |
| Sep 30, 2025 | 2.85 Mn |
| Dec 31, 2024 | -13,000.00 |
| Dec 31, 2024 | -13,000.00 |
| Sep 30, 2024 | 35.60 Mn |
| Sep 30, 2024 | 35.60 Mn |
| Jun 30, 2024 | 37.23 Mn |
| Jun 30, 2024 | 37.23 Mn |
| Mar 31, 2024 | 108.90 Mn |
| Mar 31, 2024 | 108.90 Mn |
| Dec 31, 2023 | -74,000.00 |
| Dec 31, 2023 | -74,000.00 |
| Sep 30, 2023 | 7,000.00 |
| Sep 30, 2023 | 7,000.00 |
| Jun 30, 2023 | 107,000.00 |
| Jun 30, 2023 | 107,000.00 |
| Mar 31, 2023 | 37,056.00 |
| Mar 31, 2023 | 37,056.00 |
| Mar 31, 2021 | 62.54 Mn |
| Mar 31, 2021 | 62.54 Mn |